Net loss for the three month period ended March 31, 2009 was $1,331,477, or $0.07 per share, compared with a net loss of $1,482,217, or $0.08 per share, for the three month period ended March 31, 2008. This decrease in net loss was primarily the result of a decrease in operating expenses, which was partially offset by an increase in non-cash expenses associated with the outstanding convertible notes that were issued during the year ended June 30, 2008.

Quarterly Highlights

As previously reported:

-- Senesco announced results of maximum tolerated dose, preclinical

toxicology, and efficacy / dose-range finding studies in mice for

SNS-01, the Company's multiple myeloma drug candidate.

-- Management delivered the Company's corporate presentation at the

11th Annual BIO CEO & Investor Conference.

"Senesco's goal continues to be the filing of an Investigational New Drug application for SNS-01, the Company's multiple myeloma drug candidate, before the end of calendar year 2009," said Bruce Galton, President and CEO of Senesco.

Total revenues of $75,000 for the three month period ended March 31, 2009 consisted of a milestone payment on an agricultural license agreement. Total revenues of $79,167 for the three month period ended March 31, 2008 consisted of a milestone payment and the amortized portion of previous milestone payments received in connection with certain agricultural license agreements.

Research and development expenses during the three month period ended March 31, 2009 were $540,494, compared with $474,176 during the three month period ended March 31, 2008, an increase of 14.1%. This increase was primarily a result of an expansion of Senesco's human health programs, specifically the Company's multiple myeloma research program, which was partially offset by a decrease in the cost of Senesco's research agreement with the University of Waterloo due to the strengthening of the U.S. dollar against the Canadian dollar.

General and administrative expenses were $532,245 for the three month period ended March 31, 2009, compared with $876,966 during the three month period ended March 31, 2008, a decrease of 39.3%. This decrease was primarily due to a 76.2% reduction in stock-based compensation.

As of March 31, 2009, the Company had cash and investments in the amount of $2,677,581, and working capital of $2,594,256. Senesco estimates that such amount will cover its expenses for approximately the next four months from March 31, 2009.

About Senesco Technologies, Inc.

Senesco Technologies, Inc. is a U.S. biotechnology company, headquartered in New Brunswick, NJ. Senesco has initiated preclinical research to trigger or delay cell death in mammals (apoptosis) to determine if the technology is applicable in human medicine. Accelerating apoptosis may have applications to development of cancer treatments. Delaying apoptosis may have applications to certain inflammatory and ischemic diseases.